Ghassan K. Abou-Alfa, MD, discusses the therapies being used to treat patients with hepatocellular carcinoma right now.
Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the therapies being used to treat patients with hepatocellular carcinoma (HCC) right now.
Treatment selection for patients requiring systemic therapy is dependent on many choices. Before there was only 1 choice, but now there are almost 8 choices, Abou-Alfa says. Sorafenib (Nexavar) and lenvatinib (Lenvima), which are both effective tyrosine kinase inhibitors, are available in the first-line setting. There is also a new advancement in the first line, which is the combination of atezolizumab (Tecentriq) plus bevacizumab (Avastin).
In the second-line setting, regorafenib (Stivarga) with a condition of prior sorafenib exposure is available, as well as cabozantinib (Cabometyx) in second and third line. Ramucirumab (Cyramza) is an option for patients with HCC and a high alpha-fetoprotein level of more than 400 ng/mL at baseline. Nivolumab (Opdivo) is available as a single agent or in combination with ipilimumab (Yervoy), and also pembrolizumab (Keytruda) as a single agent.
This landscape evolved quite a bit, and with the advent of new therapies, a lot of new challenges have come up, according to Abou-Alfa. A lot of clarity is needed in regard to how to sequence those therapies and how to treat patients, and the landscape is still evolving.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More